Drug intelligence / Profile preview

SCT630

Development stage: Phase 3
Lead developer: Sinocelltech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SCT630 is a biosimilar of adalimumab being developed by Sinocelltech. It is a human IgG1 monoclonal antibody specific for human TNF-α with high affinity. As a TNF-α inhibitor, SCT630 works by blocking tumor necrosis factor alpha, which can cause inflammation, pain, and autoimmune symptoms. Phase III clinical trials have demonstrated the equivalence in efficacy, safety, and immunogenicity of SCT630 to reference adalimumab in patients with moderate to severe plaque psoriasis.

Other names: Adalimumab biosimilar

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on SCT630.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCT630.

Explore the full profile